Pearson has a wide range of Clinical Outcome Assessments (COAs) that measure primary and secondary symptoms related to cognitive/neurocognitive functioning, dementia/Alzheimer's, behavioral and mental health concerns, and other factors affecting a patients’ quality of life. Each has been proven to be reliable through decades of research and is suitable for a wide range of ages with norms reflective of today’s diverse population.
Discover how our COAs are being used in clinical research, access webinars featuring experts in the field, read our blog, or review our newsletter curated with relevant industry-related content.
As we near the end of the year, it’s the perfect time to reflect on the content we’ve shared with you throughout 2024. From thought-provoking articles to expert-led webinars, and everything in between, it’s been a year full of insights, inspiration, and impactful content that resonated with all of you.
Whether you missed a post or just want to relive some of our great content, we’ve got you covered with a round-up of everything you loved in 2024.
read more
Growth scale values (GSVs) have gained traction as a more precise option for measuring outcomes in clinical trials.
read more
featuring Dr. John Harrison
The number of adults living with Alzheimer’s disease (AD) is expected to top 14 million by 2060. Not only is there no cure at this point, but current treatments haven’t been successful, and clinical trials to develop new therapeutic interventions keep failing. What’s holding back novel treatment option breakthroughs? Watch this webinar for insight into why assessment tools fail, strategies for selecting appropriate scales, and how better endpoint measures can help advance AD research.
featuring Dr. Shapiro, Dr. Eisengart, and Dr. Harmatz
Neurogenetic disorders that impact how the brain functions affect up to three percent of children, but available evaluation tools aren’t sensitive enough to detect change in their developmental skills. This poses a challenge for clinical trial sponsors who are trying to assess potential treatments. Gain more expert insight into the difficulties associated with therapy in these trial settings.
